ALNYLAM PHARMACEUTICALS, INC. Equity Securities, FV-NI, Unrealized Gain (Loss)
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $69.64 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-06.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2020-08-06
- ALNYLAM PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2020-06-30 was $45.53M.
- ALNYLAM PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2020-03-31 was $24.11M.
- ALNYLAM PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2019-06-30 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2019-03-31 was $0.00.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month |
|---|---|---|---|
| 2020-06-30 | $45.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $69.64M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $24.11M 10-Q · filed 2020-05-06 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-06 | ||
| 2018-09-30 | $5.00M 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |